±±Ê¦´ó×îз¢ÎÄ£ºPA200-µ°°×øÌåά³Ö×éµ°°×ÃÜÂëÎȶ¨²¢ÑÓ»ºË¥ÀÏ
ÈËÀ೤´ï1.8Ã×µÄDNAͨ³£²øÈÆÔÚºËÐÄ×éµ°°×ÉÏÐγɺËСÌå¡£ºËÐÄ×éµ°°××ÔÉíÓжàÖÖÐÞÊΣ¬±»ÈÏΪ×é³É¿ÉÒÅ´«ÖÁÏÂÒ»´úϸ°ûµÄ±í¹ÛÒÅ´«ÃÜÂ룬¼´¡°×éµ°°×ÃÜÂ롱£¬ÓÃÒÔÖ¸µ¼Ìض¨Ï¸°ûÀàÐÍ»ò×éÖ¯Æ÷¹ÙÖлùÒòµÄ±í´ï¡£×éµ°°×ÃÜÂëµÄ¸Ä±ä³£¼ûÓÚ¸÷ÖÖ¼²²¡ÖУ¬ÈçÖ×Áö¡¢ÐÄÔಡ¼°Ë¥Àϵȡ£Òò´Ë£¬Ì½¾¿ÉúÀí¼°²¡Àí¹ý³ÌÖÐά³Ö×éµ°°×ÃÜÂëÎȶ¨ÐԵĻúÖÆÖÁ¹ØÖØÒª¡£µ°°×øÌå¾ßÓжàÖÖµ°°×Ë®½âø»îÐÔ£¬¸ºÔðϸ°ûÄÚ´ó¶àÊýµ°°×ÖʵĽµ½â¡£
ÆÕ±é´æÔÚÓÚ¸÷ÖÖ×éÖ¯ÖеÄ26S µ°°×øÌåÓÉ20S ºËÐÄ´ß»¯¿ÅÁ£ºÍ19S µ÷½Ú¿ÅÁ£×é³É£¬´ß»¯·ºËØ»¯µ×ÎïµÄ½µ½â¡£ÒÀÀµÓÚ·ºËØ»¯½éµ¼µÄµ°°×½µ½âµÄ·¢ÏÖÓÚ2004Äê»ñµÃŵ±´¶û½±¡£
´ËÍ⣬»¹ÓÐÓÉpA28a/pA28b×÷Ϊµ÷½Ú¿ÅÁ£µÄÃâÒßµ°°×øÌ壬ÓÉpA28g×é³ÉµÄpA28g-µ°°×øÌ壬ÒÔ¼°ÓÉpA200 ×÷Ϊµ÷½Ú¿ÅÁ£µÄpA200-µ°°×øÌå¡£2013Ä꣬Éú¿ÆÔºÇñС²¨½ÌÊÚÍŶӷ¢ÏÖpA200-µ°°×øÌ帺Ôð¾«×Ó·¢Éú¼°Ìåϸ°ûDNAËðÉ˹ý³ÌÖÐÓÉÒÒõ£»¯£¨¶ø·Ç·ºËØ»¯£©½éµ¼µÄºËÐÄ×éµ°°×½µ½â£¨Cell, 2013£©£¬ ÐÞÕýÁË¿ÆÑ§½ç¹ØÓÚÌåϸ°û×éµ°°×²»½µ½âµÄÀíÂÛ¡£
×î½ü£¬ÇñС²¨½ÌÊÚ-½ªÌìϼ¸±½ÌÊÚÍŶӽøÒ»²½½ÒʾpA200-µ°°×øÌåά³Ö×éµ°°×ÃÜÂëÎȶ¨²¢ÑÓ»ºË¥ÀÏ¡£¸Ã½á¹ûÒÑÓÚ2020Äê11ÔÂÔÚTheranostics£¨SCIÓ°ÏìÒò×Ó8.579£©ÔÚÏß·¢±í£¬ÌâΪ¡°proteasome activator pA200 maintains stability of histone marks during transcription and aging¡±¡£
ÇñС²¨½ÌÊÚºÍÁÖ¿ý½ÌÊÚΪ¸ÃÎĵĹ²Í¬Í¨Ñ¶×÷Õߣ¬½ªÌìϼ¸±½ÌÊÚ¼°²©Ê¿ÉúÂíË«¡¢º«ÏÄΪ¹²Í¬µÚÒ»×÷Õß¡£²ÎÓëÕâÒ»¹¤×÷µÄ»¹ÓÐÇ廪´óѧµÄò¡Î°½ÌÊÚºÍÈÕ±¾Öþ²¨´óѧµÄTomoki Chiba½ÌÊڵȡ£¸ÃÑо¿·¢ÏÖ£¬ºËÐÄ×éµ°°×ÔÚת¼¹ý³ÌÖÐÒ²»áͨ¹ýµ°°×øÌå½µ½â¡£
½øÒ»²½£¬ËûÃǽÒʾÁËpA200-µ°°×øÌå½éµ¼ÁËÕâÒ»×éµ°°×½µ½â¹ý³Ì¡£¸üÎªÖØÒªµÄÊÇ£¬pA200µÄÇóýÏÔÖø¸Ä±ä×éµ°°×ÃÜÂëH3K4me3¼°H3K56ac·Ö²¼Î»ÖúÍÃܶȡ£pA200µÄȱʧ¼ÓËÙϸ°û¼°Ð¡Êó¸öÌåË¥ÀÏ£¬µ¼ÖÂÃâÒßÎÉÂÒ£¬½¹ÂÇ£¬²¢Ëõ¶ÌСÊóÊÙÃü¡£ ËûÃÇ»¹·¢ÏÖ£¬pA200ÔÚ½ÍĸÖеÄͬԴÎïBLM10Ò²ÓÐÀàËÆµÄ·ÀË¥ÀÏ×÷Ó㬠±íÃ÷ÕâÒ»ÏÖÏóÔÚ½ø»¯Éϸ߶ȱ£ÊØ¡£
ÔÎıêÌ⣺
proteasome activator pA200 maintains stability of histone marks during transcription and aging
https://www.thno.org/v11p1458.htm